Searchable abstracts of presentations at key conferences in endocrinology

ea0011p782 | Thyroid | ECE2006

Correlation between endogenous thyroxin and A, G, and M immunoglobulins in dysthyreosis

Laszlo A , Pascanu I , Gliga C , Schiopu A , Laszlo M

Introduction: The thyroid is a multifunctional endocrine gland which, by its hormones, affects all the organs, metabolisms and nonspecific defence of the body. The aim of this study is to establish if endogenous thyroxin (FT4) is involved in the nonspecific defence of the organism.Material and methods: 94 patients were included in the study, 47 with hyperthyroidism and 47 with hypothyroidism, 81 women, 13 men aged 7–78. FT4 was...

ea0029p1344 | Pituitary Basic | ICEECE2012

Estradiol regulates the expression of c-FLIP in anterior pituitary cells

Jaita G. , Zarate S. , Ferraris J. , Eijo G. , Magri M. , Gottardo M. , Pisera D. , Seilicovich A.

Our previous results demonstrate that estrogens increase the expression of death receptors TNFRI and Fas in the anterior pituitary and sensitize anterior pituitary cells to pro-apoptotic factors. c-FLIP is a protein that interacts with procaspases 8 and 10 modulating death receptor activity. In normal tissues, two isoforms of c-FLIP have been identified, the short isoform (c-FLIPs) and the long one (c-FLIPL). c-FLIPs has an anti-apoptotic action whereas c-FLIPL has either anti...

ea0026p570 | Cardiovascular endocrinology and lipid metabolism | ECE2011

B-type natriuretic peptide modulates the response to intravenous glucose in a placebo-controlled cross-over study in healthy volunteers

Heinisch B , Vila G , Resl M , Riedl M , Luger A , Pacini G , Clodi M

B-type natriuretic peptide (BNP) is a hormone secreted from the heart in response to volume load and serves clinically as a reliable biomarker in the diagnosis of cardiac dysfunction and heart failure. As patients with heart failure present an increased risk for developing diabetes, we aimed to investigate the role of BNP on parameters of glucose metabolism in a placebo-controlled crossover study performed in 10 healthy volunteers (25±1 years; BMI 23±1 kg/m2</su...

ea0011p493 | Endocrine tumours and neoplasia | ECE2006

Carney’s complex with acromegaly as the leading clinical condition

Fatti LM , Bertola G , Balza G , Lavezzi E , Pecori Giraldi F , Cavagnini F

Carney’s complex was first identified as the association of primary adrenal nodular dysplasia, lentigines and cardiac and skin myxomas. Several other endocrine and non-endocrine disorders were subsequently added to the complex, including pituitary tumors and melanotic Schwannomas. We herewith describe a kindred with Carney’s complex featuring acromegaly as the common denominator.Patients & methods: A 42-year-old woman first presented to our...

ea0029p1243 | Obesity | ICEECE2012

Changes in gut hormone levels and glucose homeostasis in obese patients during the first year after laparoscopic sleeve gastrectomy

Papamargaritis D. , le Roux C. , Sioka E. , Vincent R. , Kapelouzou A. , Tzovaras G. , Koukoulis G. , Zacharoulis D.

Background: Changes in gut hormone levels after laparoscopic sleeve gastrectomy (LSG) has been proposed as a possible mechanism that explains the long-term weight loss and the improvement in glucose homeostasis after bariatric operations. In this prospective study we evaluated the changes in the fasting and postprandial levels of glucagon like peptide-1 (GLP-1), peptide YY (PYY), insulin and glucose during the first postoperative year after LSG.Methods: ...

ea0029p1477 | Pituitary Clinical | ICEECE2012

Cushing’s disease: prospective assessment of factors influencing the efficacy of transsphenoidal surgery

Witek P , Zielinski G , Szamotulska K , Zgliczynski W

Introduction: Assessment of the efficacy of surgical treatment for Cushing’s disease (CD) is one of the biggest challenges in contemporary endocrinology. The aim of this study was prospective evaluation of factors influencing the result of transsphenoidal surgery for CD.Methods: The study population consisted of 36 consecutive patients with CD hospitalized in the Department of Endocrinology from 2005 to 2009 and operated on using the same surgical p...

ea0029p1551 | Steroid metabolism + action | ICEECE2012

Aromatase activity after a short-course of Letrozole administration in adult men at sea level and in men at high altitude (with or without excessive erythrocytosis)

Gonzales G. , Tapia V. , Gasco M. , Gonzales-Castaneda C.

Men living at high altitudes in Peru compared to sea level counterparts have erythrocytosis (Hemoglobin: 16–21 g/dl) or excessive erythrocytosis (Hemoglobin>21 g/dl). High testosterone (T) levels in men at high altitude (HA) were associated with excessive erythrocytosis. High androgen levels could be due to a low aromatase activity or to an elevated rate of conversion from precursors to testosterone. The aim of this study was to evaluate aromatase activity and rate of...

ea0010p61 | Pituitary | SFE2005

Reproducibility of the growth hormone response to resistance exercise in humans

Gilbert K , Thompson D , Hall G , Stokes K

ObjectiveThere is large inter-individual variation in the growth hormone (GH) response to resistance exercise, but the intra-individual variation is unknown. This study aimed to determine the reproducibility of the GH response to a 30-min resistance exercise session.DesignFollowing local Ethics Committee approval, nine male participants were familiarised before completing three trials in a random order. Durin...

ea0008p70 | Neuroendocrinology and behaviour | SFE2004

Blood Cerebrospinal Fluid Barrier (BCB) for TSH, Prolactin and Insulin in Pregnancy

Lutescu I , Gussi IL , Banceanu G , Coculescu M

The blood-brain barrier for peptide hormones is protective for the maternal brain.OBJECTIVE: To compare peptide hormone levels on the two sides of the blood cerebrospinal fluid barrier in pregnant, non pregnant and menopausal women.METHODS: We investigated, with the approval of the local ethics committee, 35 healthy pregnant women at term, aged 21-41 years (group G), 27 non-pregnant women aged 21-43 years (group C) and 15 menopausa...

ea0029p353 | Clinical case reports - Pituitary/Adrenal | ICEECE2012

Long-term efficacy and safety of pasireotide in Cushing’s disease: a 36-month case report

Ning G. , Wang W. , Maldonado M. , Trovato A. , Zhou W.

Background: A recent, large phase III study (n=162) showed that treatment with pasireotide rapidly decreased urinary free cortisol (UFC) levels and improved signs and symptoms in patients with Cushing’s disease. Here, we report the experience of a patient enrolled in this trial who received pasireotide for 36 months.Results: A 31-year-old male presented in June 2008 with persistent Cushing’s disease despite two previous pituitary surgica...